EGFR and non-small cell lung carcinoma: Therefore, EGFR-TKIs have been recommended as the standard of care for first-line treatment for EGFR-mutant NSCLC, especially for those who harbored a drug sensitivity-associated mutation including exon 19 deletion (19Del) and exon 21 L858R.